Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 5/2021

01-10-2021 | Atrioventricular Block | Case Presentation Corner

Asystole following Regadenoson administration: Review of literature, risk factors and management

Authors: Talal Asif, MD, Katherine Lee Chuy, MD, Saurabh Malhotra, MD, MPH, FASNC

Published in: Journal of Nuclear Cardiology | Issue 5/2021

Login to get access

Abstract

Regadenoson, a selective A2A receptor agonist, is widely used for vasodilator stress myocardial perfusion imaging and has a superior adverse effect profile when compared with other agents. However, with widespread use, there have been several reported cases of Regadenoson induced bradyarrhythmias and even asystole in patients with no known conduction system disease. In this article, we report a case of asystole following Regadenoson administration, evaluate mechanisms and risk factors for Regadenoson induced bradyarrhythmias to better identify patients at risk. We also review the available treatment options and propose recommendations for limiting its risk.
Literature
1.
Hage FG. Regadenoson for myocardial perfusion imaging: Is it safe? J Nucl Cardiol. 2014;21(5):871-6.CrossRef
2.
Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14(5):645-58.CrossRef
3.
Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity. JACC Cardiovasc Imaging. 2008;1(3):307-16.CrossRef
4.
Grady EC, Barron JT, Wagner RH. Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine. J Nucl Cardiol. 2011;18(3):521-5.CrossRef
5.
Rosenblatt J, Mooney D, Dunn T, Cohen M. Asystole following regadenoson infusion in stable outpatients. J Nucl Cardiol. 2014;21(5):862-8.CrossRef
6.
Agarwal V, DePuey EG. Advanced heart block and unresponsiveness after regadenoson administration during myocardial SPECT study. Int J Cardiol. 2014;176(2):e49-51.CrossRef
7.
Brinkert M, Reyes E, Walker S, et al. Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy. Eur J Nucl Med Mol Imaging. 2014;41(3):511-21.CrossRef
8.
Kureshi F, Abdallah MS, Bateman TM. Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of. J Nucl Cardiol. 2017;24(6):2019-24.CrossRef
9.
Mustehsan MH, Gandhi H, Hasani A, Rashid SMI, Goldberg Y. Regadenoson-induced asystole and ischemic EKG changes in the setting of underlying coronary disease. J Nucl Cardiol. 2019;27(2):698-701.CrossRef
10.
Andrikopoulou E, Hage FG. Adverse effects associated with regadenoson myocardial perfusion imaging. J Nucl Cardiol. 2018;25(5):1724-31.CrossRef
11.
12.
Derbas LA, Thomas GS, Medina CA, Abdel-Karim AA, Saeed IM, Bateman TM. Severe Bradycardia and Asystole Following Regadenoson in Pharmacological Myocardial Perfusion Imaging: Cases and Treatment Recommendations. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1288-90.CrossRef
13.
Pandit A, Unzek Freiman S. Complete heart block associated with regadenoson: a real side effect. J Nucl Cardiol. 2012;19(6):1236-9.CrossRef
14.
Andrikopoulou E, Morgan CJ, Brice L, et al. Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis. J Nucl Cardiol. 2019;26(2):616-28.CrossRef
15.
Massalha S, Reizberg I, Israel O, et al. Conduction abnormalities during dipyridamole stress testing. J Nucl Cardiol. 2017;24(2):405-9.CrossRef
16.
Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol. 1994;23(2):384-9.CrossRef
17.
Sun H, Tian Y, Zheng L, Pan Q, Xie B. Electrocardiographic profile of adenosine pharmacological stress testing. Exp Ther Med. 2015;9(4):1178-84.CrossRef
18.
Underwood SR, Latus KA, Reyes E, Standbridge K, Walker S, Wechalekar K. Regadenoson-induced bradycardia and hypotension: possible mechanism and antidote. J Nucl Cardiol. 2014;21(5):1040.CrossRef
19.
Hage FG, Iskandrian AE. Serious complications associated with regadenoson administration for myocardial perfusion imaging: a commentary. J Nucl Cardiol. 2014;21(5):877-9.CrossRef
20.
Lee HC, Tl Huang K, Shen WK. Use of antiarrhythmic drugs in elderly patients. J Geriatr Cardiol. 2011;8(3):184-94.CrossRef
21.
Curtis AB, Karki R, Hattoum A, Sharma UC. Arrhythmias in Patients ≥80 Years of Age: Pathophysiology, Management, and Outcomes. J Am Coll Cardiol. 2018;71(18):2041-57.CrossRef
22.
Manolio TA, Furberg CD, Rautaharju PM, et al. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol. 1994;23(4):916-25.CrossRef
23.
Jones PP, Christou DD, Jordan J, Seals DR. Baroreflex buffering is reduced with age in healthy men. Circulation. 2003;107(13):1770-4.CrossRef
24.
Reardon M, Malik M. Changes in heart rate variability with age. Pacing Clin Electrophysiol. 1996;19(11 Pt 2):1863-6.CrossRef
25.
Podrazik PM, Schwartz JB. Cardiovascular pharmacology of aging. Cardiol Clin. 1999;17(1):17-34.CrossRef
26.
Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47(7):825-33.CrossRef
27.
Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013;20(2):205-13.CrossRef
28.
Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol. 2010;105(1):133-5.CrossRef
29.
Palani G, Husain Z, Salinas RC, Karthikeyan V, Karthikeyan AS, Ananthasubramaniam K. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol. 2011;18(4):605-11.CrossRef
30.
Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol. 2010;105(6):839-43.CrossRef
31.
Lieu HD, Shryock JC, von Mering GO, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14(4):514-20.CrossRef
32.
Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016;23(3):606-39.CrossRef
Metadata
Title
Asystole following Regadenoson administration: Review of literature, risk factors and management
Authors
Talal Asif, MD
Katherine Lee Chuy, MD
Saurabh Malhotra, MD, MPH, FASNC
Publication date
01-10-2021
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 5/2021
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-020-02136-x

Other articles of this Issue 5/2021

Journal of Nuclear Cardiology 5/2021 Go to the issue

Review of the Literature

Cardiovascular disease in the literature: A selection of recent original research papers

Original Article

Clinical significance of corrected relative flow reserve derived from 13N-ammonia positron emission tomography combined with coronary computed tomography angiography

Leadership Page

ASNC Statements of Principles on the Issue of Multimodality Imaging

ORIGINAL ARTICLE

Vascular uptake on 18F-sodium fluoride positron emission tomography: precursor of vascular calcification?

Original Article

18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis

Letter to the Editor

PET/CT for endocarditis in the ACC/AHA 2020 valve guidelines: Ready for prime time?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits